CJC-1295 No DAC + Ipamorelin is a dual-peptide research blend combining 5mg CJC-1295 without DAC (Modified GRF 1-29) with 5mg Ipamorelin, providing a total peptide content of 10mg.

The combination is primarily studied in relation to the growth hormone (GH)/IGF-1 axis, bringing together two peptides that interact with different receptor pathways involved in endogenous growth-hormone release.

What is CJC-1295 No DAC?

CJC-1295 without DAC, commonly referred to as Modified GRF (1-29), is a modified analogue of growth hormone-releasing hormone (GHRH).

It interacts with GHRH receptors on pituitary somatotroph cells, making it an important research compound for investigating pituitary signalling and pulsatile growth-hormone release.

The “No DAC” designation means that the peptide does not contain the Drug Affinity Complex used in the longer-acting CJC-1295 DAC formulation.

This distinction makes CJC-1295 No DAC a considerably shorter-acting research compound than the DAC-containing form.